ResMed Inc. (NYSE:RMD) insider Rajwant Sodhi sold 1,350 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $144.38, for a total value of $194,913.00.
Shares of ResMed stock opened at $143.25 on Thursday. The company has a current ratio of 2.11, a quick ratio of 1.46 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $21.21 billion, a PE ratio of 39.12, a price-to-earnings-growth ratio of 2.82 and a beta of 0.41. The business’s 50-day moving average price is $135.58 and its 200-day moving average price is $125.55. ResMed Inc. has a 12 month low of $90.64 and a 12 month high of $149.96.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $0.93 EPS for the quarter, beating the consensus estimate of $0.87 by $0.06. The firm had revenue of $681.06 million for the quarter, compared to analyst estimates of $660.87 million. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The company’s revenue was up 15.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.81 EPS. As a group, analysts predict that ResMed Inc. will post 4.04 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be given a dividend of $0.39 per share. The ex-dividend date is Wednesday, November 6th. This represents a $1.56 annualized dividend and a dividend yield of 1.09%. ResMed’s dividend payout ratio (DPR) is presently 42.86%.
RMD has been the topic of a number of research analyst reports. ValuEngine lowered ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, October 25th. UBS Group upgraded ResMed from a “neutral” rating to a “buy” rating and upped their target price for the stock from $122.00 to $140.00 in a research note on Monday, July 29th. Finally, Goldman Sachs Group upgraded ResMed from a “neutral” rating to a “buy” rating in a research report on Monday, July 29th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $121.50.
Institutional investors have recently made changes to their positions in the company. Westside Investment Management Inc. bought a new position in shares of ResMed during the 2nd quarter valued at about $26,000. Squar Milner Financial Services LLC increased its position in shares of ResMed by 342.9% during the 3rd quarter. Squar Milner Financial Services LLC now owns 217 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 168 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in ResMed during the 2nd quarter valued at about $40,000. CSat Investment Advisory L.P. boosted its holdings in ResMed by 97.0% during the 2nd quarter. CSat Investment Advisory L.P. now owns 388 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 191 shares during the period. Finally, AdvisorNet Financial Inc boosted its holdings in ResMed by 26.0% during the 3rd quarter. AdvisorNet Financial Inc now owns 392 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 81 shares during the period. Hedge funds and other institutional investors own 66.45% of the company’s stock.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Recommended Story: Asset Allocation and Your Retirement
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.